title: Effect of antiangiogenic treatment on peritoneal endometriosis-associated nerve fibers.
abstract: OBJECTIVE
  To investigate the effect of antiangiogenic treatment on experimental endometriotic lesion nerve fibers.
  
  
  METHODS
  Heterologous mouse model of endometriosis.
  
  
  METHODS
  University Institute IVI, University Hospital La Fe.
  
  
  METHODS
  Ovariectomized nude mice (n = 16) receiving human endometrial fragments from oocyte donors (n = 4).
  
  
  METHODS
  Endometrium fragments stuck in the peritoneum of 5-week-old female nude mice treated with vehicle (n = 8) and antiangiogenic agent cabergoline (n = 8; Cb(2,) 0.05 mg/kg/day) for 14 days.
  
  
  METHODS
  Immunofluorescence analysis of von-Willebrand factor (vWF) and vascular smooth muscle cells (αSMA) for evaluating the number of immature blood vessels (IBV) and microvascular density (MVD); immunochemical analysis of protein-gene product 9.5 (PGP 9.5) to assess nerve fibers density (NFD), and blue toluidine staining to confirm presence of mast cells and macrophages in endometriotic lesions.
  
  
  RESULTS
  All the results were quantified by morphometric techniques. The IBV, NFD, and number of macrophages and mast cells were statistically significantly decreased in the Cb2-treated group when compared with controls.
  
  
  CONCLUSIONS
  Antiangiogenic treatment statistically significantly diminishes new blood vessel formation after macrophage, mast cell, and nerve fiber reduction, providing a rationale to test antiangiogenic agents as a novel therapeutic approach to severe pelvic pain associated with human peritoneal endometriosis.
authors.affiliation: Unidad de Genética, Hospital Universitario y Politécnico La Fe, Valencia, Spain. edurnenovella@yahoo.es
authors.forename: Edurne
authors.initials: E
authors.lastname: Novella-Maestre
authors.forename: Sonia
authors.initials: S
authors.lastname: Herraiz
authors.forename: José María
authors.initials: JM
authors.lastname: Vila-Vives
authors.forename: Carmen
authors.initials: C
authors.lastname: Carda
authors.forename: Amparo
authors.initials: A
authors.lastname: Ruiz-Sauri
authors.forename: Antonio
authors.initials: A
authors.lastname: Pellicer
mesh_terms: D000199:Actins / Q000378:metabolism; D020533:Angiogenesis Inhibitors / Q000494:pharmacology*; D000818:Animals; D015415:Biomarkers / Q000378:metabolism; D000077465:Cabergoline; D004195:Disease Models, Animal; D004715:Endometriosis / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism / Q000473:pathology; D004717:Endometrium / Q000098:blood supply / Q000187:drug effects* / Q000294:innervation / Q000637:transplantation; D004873:Ergolines / Q000494:pharmacology*; D005260:Female; D005455:Fluorescent Antibody Technique; D006801:Humans; D007150:Immunohistochemistry; D008264:Macrophages / Q000187:drug effects / Q000473:pathology; D008407:Mast Cells / Q000187:drug effects / Q000473:pathology; D051379:Mice; D008819:Mice, Nude; D055806:Microvessels / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D009389:Neovascularization, Pathologic; D009412:Nerve Fibers / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D010052:Ovariectomy; D010532:Peritoneal Diseases / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism / Q000473:pathology; D013997:Time Factors; D014841:von Willebrand Factor / Q000378:metabolism
chemical_list: D000199:Actins; D020533:Angiogenesis Inhibitors; D015415:Biomarkers; D004873:Ergolines; D014841:von Willebrand Factor; D000077465:Cabergoline